BRCA1 and ovarian carcinoma: Differences between the DA and control groups were no longer significant for the valuation of prophylactic mastectomy (P=0.13), the valuation of prophylactic oophorectomy (P=0.15), and risk accuracy of BRCA1/2 related ovarian cancer risk (P=0.18).